查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1419140

血浆治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：类型、来源、应用、最终用户和地理位置

Plasma Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: Type, Source, Application, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

血浆治疗市场预计将从2022年的3.9亿美元成长到2030年的10.97亿美元；预计2022年至2030年市场CAGR为13.80%。

推动市场成长的关键因素包括人们（尤其是老年人口）骨科疾病病例的增加、运动员关节和肌肉损伤数量的增加以及对微创整容手术的需求激增。

富含血小板血浆（PRP）是一种再生医学，可以放大血液中的天然生长因子来治癒组织。它需要利用从疾病中成功康復的个体获得的血浆来解决一系列医疗问题并促进康復过程。 PRP 治疗可应用于治疗关节损伤的骨科、皮肤再生手术以及牙科组织修復

骨科疾病和肌肉损伤病例的增加以及 PRP 在美容手术中的使用增加推动了血浆治疗市场的成长

根据世界卫生组织 (WHO) 2023 年发布的统计数据，2019 年全球约有 5.28 亿人患有骨关节炎 (OA)，较 1990 年增加了 113%。2020 年 12 月发表在 PubMed Central 上的文章指出，由于血浆中含有丰富的生长因子和细胞因子，PRP 的使用提供了组织修復的潜力，这对于启动和调节软组织和硬组织的再生微环境至关重要。 PRP疗法可用于骨折、韧带、肌肉和肌腱损伤、週边神经损伤、关节软骨损伤和骨关节炎的癒合。因此，骨科和组织修復手术中对血浆疗法的需求很高。

此外，PRP也用于美容手术，以实现嫩肤、抗衰老和其他美容手术。 2021 年 11 月 PubMed Central 发表的一篇综述评估了 73 项研究，其中 45 项研究专注于 PRP 单一疗法，而 35 项研究研究了 PRP 与微针联合治疗的效果。因此，这些疗法具有良好的耐受性并适合所有光型。多种病症均取得了积极的治疗效果，包括皮肤年轻化、疤痕修復、脱髮、色素性疾病、地衣硬化、麻风病引起的周边神经病变、斑块状牛皮癣和指甲疾病。

因此，PRP在整容手术中的使用有助于血浆治疗市场的成长。

市场机会

PRP 在合併治疗的应用

PRP 疗法是一种不断发展的治疗方法，在皮肤科中有多种应用，特别是用于头髮修復、皮肤年轻化、痤疮疤痕、真皮增强和扩张皮纹。将 PRP 与雷射疗法、微针疗法、真皮填充剂和自体脂肪移植结合使用，由于协同效应，可以带来更好的美容效果。然而，需要针对特定情况对 PRP 治疗方案进行标准化。 PRP在皮肤病学领域具有巨大潜力，其治疗应用不断扩大。已经进行了许多研究来评估 PRP 在多种皮肤病（例如雄性秃、白斑和皮肤年轻化）的联合药物治疗中的效果。例如，PubMed Central 于2021 年发表的一项研究“在雄激素性脱髮的联合药物治疗中添加富含血小板的血浆的评估”，对126 名患有雄激素性脱髮(AGA) 的患者进行了研究，AGA 是一种常见的脱髮疾病，该研究得出的结论是，将「PRP 与微针」整合到 AGA 的联合药物治疗中可以提高其疗效，并缩短获得最大改善所需的时间。

同样，在 Wiley Online Library 于 2020 年 11 月发表的另一篇文章中，进行了一项研究来评估治疗白斑症的各种联合治疗策略。该研究包括 11 项研究，670 个病例。结论是，与单一疗法相比，结合使用 308 nm 准分子雷射和 PRP 时，色素沉着的临床改善明显更高。类似地，点阵二氧化碳雷射和 PRP 的结合导致了更高的平均色素沉着改善程度。

因此，PRP 联合疗法的推出正在为血浆治疗市场创造各种机会。

分部概览

血浆治疗市场根据类型、来源、应用、最终产品和最终用户进行细分。从类型来看，市场分为纯PRP、富白血球PRP、纯富血小板纤维蛋白及富白血球纤维蛋白。纯富含血小板的纤维蛋白细分市场在 2022 年占据最大的市场份额，预计 2022-2030 年CAGR最高。富含白血球的 PRP (LR-PRP) 是一种中性粒细胞（白血球）浓度高于基线水平的 PRP。它通常与促发炎作用有关。然而，在某些情况下，LR-PRP 可能有助于刺激体内炎症，以提示肌腱病等慢性疾病。

血浆治疗市场依来源分为自体血浆和同种异体血浆。自体部分在 2022 年占据市场主导地位，同种异体部分预计在 2022-2030 年期间将录得更高的CAGR。自体 PRP 注射是一种安全可靠的生物技术，用于治疗不同的肌肉骨骼疾病。 PRP注射可透过抑制发炎细胞激素的产生、促进滑膜纤维母细胞的生长，有效支持类风湿性关节炎等慢性自体免疫发炎疾病患者的初级治疗。

目录

第 1 章：简介

  • 研究范围
  • 市场定义、假设与限制
  • 市场区隔

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：血浆治疗市场格局

  • 概述
  • PEST分析

第 5 章：血浆治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：血浆治疗市场 - 全球市场分析

  • 血浆治疗 - 全球市场概览
  • 血浆治疗 - 全球市场与 2030 年预测

第 7 章：血浆治疗市场 - 收入分析 - 按类型，2020-2030 年

  • 概述
  • 纯PRP
  • 富含白血球的PRP
  • 纯富含血小板的纤维蛋白
  • 富含白血球的纤维蛋白

第 8 章：血浆治疗市场 - 收入分析 - 按来源划分，2020-2030 年

  • 概述
  • 自体
  • 同种异体

第 9 章：血浆治疗市场 - 收入分析 -按应用，2020-2030 年

  • 概述
  • 骨科
  • 皮肤科
  • 心肌损伤
  • 牙科
  • 神经损伤
  • 其他的

第 10 章：血浆治疗市场 - 收入分析 - 按最终产品生产，2020-2030 年

  • 概述
  • 白蛋白
  • 免疫球蛋白 G (IgG)
  • 其他的

第 11 章：血浆治疗市场 - 收入分析 - 按最终用户，2020-2030 年

  • 概述
  • 医院和诊所
  • 研究机构
  • 门诊手术中心

第 12 章：血浆治疗市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 13 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第14章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 15 章：血浆治疗市场 - 主要公司概况

  • BioLife Plasma Services

注意 - 将为以下公司列表提供类似信息

  • 武田药品工业株式会社
  • 生物测试公司
  • 中超有限公司
  • 南澳州格里福斯
  • 凯德瑞安公司
  • 免疫泰克生物中心
  • 生物製品实验室有限公司
  • 中国生物製品控股有限公司
  • 奥克塔製药公司
  • 起源公司

第 16 章：附录

  • 词彙表
  • 关于 Insight Partners
  • 市场情报云
简介目录
Product Code: TIPRE00004429

The plasma therapy market is expected to grow from US$ 390 million in 2022 to US$ 1,097 million by 2030; the market is estimated to register a CAGR of 13.80% from 2022 to 2030.

Key factors driving the market growth include the rising cases of orthopedic disorders in people, especially in the geriatric population, the rising number of joint and muscle injuries in athletes, and the surging demand for minimally invasive cosmetic procedures.

Platelet-rich plasma (PRP) is a form of regenerative medicine that amplifies natural growth factors in blood to heal tissue. It entails the utilization of the blood plasma obtained from individuals who have successfully recovered from an illness to address the range of medical conditions and foster the process of healing. PRP treatments find applications in orthopedics for the treatment of joint injuries, dermatology in skin rejuvenation procedures, and dentistry for tissue repair

Rising Cases of Orthopedic Disorders and muscle Injuries and Increasing Use of PRP in Aesthetic Procedures Drive Plasma Therapy Market Growth

According to statistics published by the World Health Organization (WHO) in 2023, ~528 million people across the world were living with osteoarthritis (OA) in 2019, representing an increase of 113% since 1990. An article published in PubMed Central in December 2020 states that the use of PRP offers potential for tissue repair due to the abundance of growth factors and cytokines in this plasma, which are crucial in initiating and modulating regenerative microenvironments for both soft and hard tissues. PRP therapy can be used in the healing of bone fractures, ligament, muscle, and tendon injuries, peripheral nerve injuries, articular cartilage lesions, and osteoarthritis. Therefore, there is a high demand for plasma therapies in orthopedic and tissue repair procedures.

Moreover, PRP is used in cosmetic surgeries for skin rejuvenation, anti-aging, and other aesthetic procedures. Out of 73 studies evaluated in a review published in PubMed Central in November 2021, 45 studies focused on PRP monotherapy, while 35 studies investigated the effects of PRP in combination with microneedling. As a result, the therapies were well-tolerated and suitable for all phototypes. Positive treatment outcomes were identified for various conditions, including skin rejuvenation, scar revision, alopecia, pigmentary disorders, lichen sclerosis, leprosy-induced peripheral neuropathy, plaque psoriasis, and nail disorders.

Therefore, the use of PRP in cosmetic surgeries contributes to the growth of the plasma therapy market.

Market Opportunity

Use of PRP in Combination Therapies

PRP therapy is an evolving treatment method with several applications in dermatology, particularly for hair restoration, skin rejuvenation, acne scars, dermal augmentation, and striae distensae. Using PRP together with laser therapies, microneedling, dermal fillers, and autologous fat grafting can result in better aesthetic outcomes due to synergistic effects. However, there is a need for standardization of PRP treatment protocols for specific conditions. PRP has great potential in dermatology, and its therapeutic applications are continuously expanding. Many studies have been conducted to assess the effect of PRP in combined medical therapy for various dermatological disorders such as androgenetic alopecia, vitiligo, and skin rejuvenation. For instance, a study, "Evaluation of adding platelet-rich plasma to combined medical therapy in androgenetic alopecia," published by PubMed Central in 2021, was carried out on 126 patients suffering from Androgenetic alopecia (AGA), a common hair loss disorder, the study concluded that the integration of "PRP with micro-needling" to the combined medical therapy in AGA boosts its efficacy and reduces the time required for maximum improvement.

Similarly, in another article published by Wiley Online Library in November 2020, a study was carried out to assess various combination therapy strategies for treating vitiligo. The study included eleven studies with 670 cases. It concluded that in comparison to monotherapy, the clinical improvement of re-pigmentation was significantly higher when using a combination of 308-nm excimer laser and PRP. Similarly, a combination of fractional carbon dioxide laser and PRP resulted in a higher mean improvement grade of re-pigmentation.

Therefore, the introduction of PRP-combination therapies is creating various opportunities in the plasma therapy market.

SEGMENTAL OVERVIEW

The plasma therapy market is segmented on the basis of type, source, application, end product, and end user. In terms of type, the market is segmented into pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich fibrin. The pure platelet-rich fibrin segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030. Leukocyte-rich PRP (LR-PRP) is a type of PRP that has a higher concentration of neutrophils (white blood cells) than the baseline level. It is generally associated with proinflammatory effects. However, in some cases, LR-PRP can be beneficial to stimulate inflammation in the body to indicate a chronic condition such as tendinopathy.

The plasma therapy market, by source, is bifurcated into autologous and allogeneic. The autologous segment dominated the market in 2022, and the allogeneic segment is anticipated to record a higher CAGR during 2022-2030. Autologous PRP injection is a secure and reliable biological technique that is used for the treatment of different musculoskeletal disorders. PRP injection can effectively support the primary treatment of patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis by suppressing the production of inflammatory cytokines and promoting the growth of synovial fibroblasts.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Plasma Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Plasma Therapy Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Plasma Therapy Market - Global Market Analysis

  • 6.1 Plasma Therapy - Global Market Overview
  • 6.2 Plasma Therapy - Global Market and Forecast to 2030

7. Plasma Therapy Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 7.1 Overview
  • 7.2 Pure PRP
  • 7.3 Leukocyte-Rich PRP
  • 7.4 Pure Platelet-Rich Fibrin
  • 7.5 Leukocyte-Rich Fibrin

8. Plasma Therapy Market - Revenue Analysis (USD Million) - By Source, 2020-2030

  • 8.1 Overview
  • 8.2 Autologous
  • 8.3 Allogenic

9. Plasma Therapy Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 9.1 Overview
  • 9.2 Orthopedic
  • 9.3 Dermatology
  • 9.4 Cardiac Muscle Injury
  • 9.5 Dental
  • 9.6 Nerve Injury
  • 9.7 Others

10. Plasma Therapy Market - Revenue Analysis (USD Million) - By End Products Produce , 2020-2030

  • 10.1 Overview
  • 10.2 Albumin
  • 10.3 Immunoglobulin G (IgG)
  • 10.4 Others

11. Plasma Therapy Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 11.1 Overview
  • 11.2 Hospitals and Clinics
  • 11.3 Research Institutes
  • 11.4 Ambulatory Surgical Centers

12. Plasma Therapy Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 12.1 North America
    • 12.1.1 North America Plasma Therapy Market Overview
    • 12.1.2 North America Plasma Therapy Market Revenue and Forecasts to 2030
    • 12.1.3 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Type
    • 12.1.4 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Source
    • 12.1.5 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Application
    • 12.1.6 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By End Products Produce
    • 12.1.7 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By End User
    • 12.1.8 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Countries
      • 12.1.8.1 United States Plasma Therapy Market
        • 12.1.8.1.1 United States Plasma Therapy Market, by Type
        • 12.1.8.1.2 United States Plasma Therapy Market, by Source
        • 12.1.8.1.3 United States Plasma Therapy Market, by Application
        • 12.1.8.1.4 United States Plasma Therapy Market, by End Products Produce
        • 12.1.8.1.5 United States Plasma Therapy Market, by End User
      • 12.1.8.2 Canada Plasma Therapy Market
        • 12.1.8.2.1 Canada Plasma Therapy Market, by Type
        • 12.1.8.2.2 Canada Plasma Therapy Market, by Source
        • 12.1.8.2.3 Canada Plasma Therapy Market, by Application
        • 12.1.8.2.4 Canada Plasma Therapy Market, by End Products Produce
        • 12.1.8.2.5 Canada Plasma Therapy Market, by End User
      • 12.1.8.3 Mexico Plasma Therapy Market
        • 12.1.8.3.1 Mexico Plasma Therapy Market, by Type
        • 12.1.8.3.2 Mexico Plasma Therapy Market, by Source
        • 12.1.8.3.3 Mexico Plasma Therapy Market, by Application
        • 12.1.8.3.4 Mexico Plasma Therapy Market, by End Products Produce
        • 12.1.8.3.5 Mexico Plasma Therapy Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 12.2 Europe
    • 12.2.1 Germany
    • 12.2.2 France
    • 12.2.3 Italy
    • 12.2.4 Spain
    • 12.2.5 United Kingdom
    • 12.2.6 Rest of Europe
  • 12.3 Asia-Pacific
    • 12.3.1 Australia
    • 12.3.2 China
    • 12.3.3 India
    • 12.3.4 Japan
    • 12.3.5 South Korea
    • 12.3.6 Rest of Asia-Pacific
  • 12.4 Middle East and Africa
    • 12.4.1 South Africa
    • 12.4.2 Saudi Arabia
    • 12.4.3 U.A.E
    • 12.4.4 Rest of Middle East and Africa
  • 12.5 South and Central America
    • 12.5.1 Brazil
    • 12.5.2 Argentina
    • 12.5.3 Rest of South and Central America

13. Industry Landscape

  • 13.1 Mergers and Acquisitions
  • 13.2 Agreements, Collaborations, Joint Ventures
  • 13.3 New Product Launches
  • 13.4 Expansions and Other Strategic Developments

14. Competitive Landscape

  • 14.1 Heat Map Analysis by Key Players
  • 14.2 Company Positioning and Concentration

15. Plasma Therapy Market - Key Company Profiles

  • 15.1 BioLife Plasma Services
    • 15.1.1 Key Facts
    • 15.1.2 Business Description
    • 15.1.3 Products and Services
    • 15.1.4 Financial Overview
    • 15.1.5 SWOT Analysis
    • 15.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 15.2 Takeda Pharmaceutical Company Limited
  • 15.3 Biotest AG
  • 15.4 CSL Ltd.
  • 15.5 Grifols, S.A.
  • 15.6 Kedrion S.p.A
  • 15.7 ImmunoTek Bio Centers
  • 15.8 Bio Products Laboratory Ltd.
  • 15.9 China Biologic Products Holdings, Inc.
  • 15.10 Octapharma AG
  • 15.11 Origin, Inc.

16. Appendix

  • 16.1 Glossary
  • 16.2 About The Insight Partners
  • 16.3 Market Intelligence Cloud